This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GTCR, Surmodics argue no overlap with Biocoat despite US FTC claims

By Wesley Brown ( March 28, 2025, 19:58 GMT | Insight) -- GTCR, a private equity firm, told a US federal court that it won’t control over 50 percent of the market for outsourced hydrophilic coatings after acquiring Surmodics because the latter does not compete directly with GTCR-owned Biocoat. Both parties filed answers to the US Federal Trade Commission's March 6 complaint seeking to block the deal worth approximately $627 million, and argued that thermal and UV curing processes for medical device coatings are different markets.GTCR, a private equity firm, told a US federal court that it won’t control over 50 percent of the market for outsourced hydrophilic coatings after acquiring Surmodics because the latter does not compete directly with GTCR-owned Biocoat....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login